AAP
GLSI icon

Arax Advisory Partners’s Greenwich LifeSciences GLSI Stock Holding History

Arax Advisory Partners’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24 Buy
+1
New +$26 ﹤0.01% 3700
2025
Q4 		– Sell
-123
Closed -$1.22K – 4265
2025
Q3 		$1.22K Buy
+123
New +$1.39K ﹤0.01% 3211

Other funds holding GLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arax Advisory Partners's GLSI Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Greenwich LifeSciences (GLSI) in Q1 2026: 1 share worth $24. The stake represents ﹤0.01% of the portfolio and ranks #3700 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in GLSI as recently as Q3 2025.

Arax Advisory Partners first reported a position in GLSI in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.22K in Q3 2025. 64 funds tracked by Wall St. Rank hold GLSI as of Q1 2026.

  • Arax Advisory Partners held 1 share of Greenwich LifeSciences worth $24 as of Q1 2026.
  • Greenwich LifeSciences was a new Arax Advisory Partners position in Q1 2026.
  • Greenwich LifeSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3700 holding.
  • Arax Advisory Partners first reported a position in Greenwich LifeSciences in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Greenwich LifeSciences position peaked at $1.22K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.